Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
The overview and definition of lymphoma provides essential insight into a group of blood cancers that begin in the lymphatic system. This page is designed for international patients and their families who are seeking clear, reliable information about lymphoma before making treatment decisions. According to the World Health Organization, lymphoma accounts for roughly 10% of all cancers worldwide, highlighting the importance of early awareness. In the following sections, you will find a detailed explanation of the disease, its causes, how it presents, diagnostic pathways, treatment modalities, and supportive care options available at Liv Hospital.
Our aim is to present an overview and definition that demystifies complex medical terminology while maintaining clinical accuracy. Whether you are a newly diagnosed patient, a caregiver, or a health‑conscious individual, this resource will help you understand the condition and explore the comprehensive services offered by a JCI‑accredited institution.
By reviewing this overview and definition, you will gain a clearer picture of what to expect throughout the care journey, from initial consultation to long‑term follow‑up.
Lymphoma is broadly categorized into two major families: Hodgkin lymphoma (HL) and non‑Hodgkin lymphoma (NHL). Each family encompasses several subtypes that differ in cellular origin, behavior, and response to therapy.
Hodgkin lymphoma is characterized by the presence of Reed‑Sternberg cells and typically follows a predictable pattern of spread. In contrast, non‑Hodgkin lymphoma includes a diverse group of over 60 subtypes, ranging from indolent (slow‑growing) to aggressive forms.
Understanding these classifications is crucial because treatment strategies and prognoses vary significantly between subtypes. At Liv Hospital, a multidisciplinary team conducts precise histopathological and molecular analyses to accurately identify the specific lymphoma type, ensuring personalized care.
While the exact cause of lymphoma remains uncertain, research has identified several factors that increase susceptibility. Recognizing these risk elements can aid in early detection and preventive counseling.
It is important to note that having one or more risk factors does not guarantee development of lymphoma, just as many patients are diagnosed without identifiable risk factors. Lifestyle modifications, such as smoking cessation and maintaining a healthy immune system, can mitigate some modifiable risks.
Lymphoma often presents with subtle, nonspecific symptoms that can be mistaken for common infections. Early recognition of warning signs facilitates prompt evaluation and improves outcomes.
Because these manifestations overlap with many benign conditions, a thorough clinical evaluation is essential. At Liv Hospital, international patients benefit from a streamlined appointment system that includes virtual pre‑consultations, enabling early triage based on symptom profiles.
Accurate diagnosis relies on a combination of imaging, laboratory, and tissue‑based studies. Staging determines the extent of disease spread and guides therapeutic planning.
Staging follows the Ann Arbor system, ranging from Stage I (localized) to Stage IV (disseminated). The comprehensive diagnostic pathway at Liv Hospital integrates state‑of‑the‑art imaging with expert pathology review, ensuring each patient receives an accurate stage classification.
Therapeutic strategies for lymphoma are tailored to subtype, stage, patient age, and overall health. Conventional modalities remain the cornerstone of care, while innovative treatments are expanding the therapeutic arsenal.
Liv Hospital’s oncology department collaborates with international research networks, providing patients access to clinical trials investigating novel checkpoint inhibitors, bispecific antibodies, and personalized vaccine approaches. A multidisciplinary tumor board reviews ea
Beyond medical treatment, comprehensive care addresses psychosocial, nutritional, and rehabilitative needs. Survivorship programs are essential for maintaining quality of life.
The comprehensive overview and definition presented here underscores that lymphoma is a manageable disease when approached with a coordinated, patient‑centered strategy. Liv Hospital’s 360‑degree international patient services ensure that every aspect of the journey—from diagnosis to survivorship—is supported with expertise and compassion.
Liv Hospital is a JCI‑accredited private medical center in Istanbul that specializes in delivering world‑class oncology care to patients from around the globe. Our multidisciplinary team combines advanced diagnostic technology, cutting‑edge treatment protocols, and personalized support services, including visa assistance, airport transfers, and multilingual interpreters. By choosing Liv Hospital, international patients gain access to a seamless, high‑quality experience that prioritizes both clinical excellence and comfort.
Ready to take the next step in your lymphoma care journey? Contact Liv Hospital today to schedule a personalized consultation and discover how our expert team can guide you toward recovery.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
People with inherited immune‑system gene mutations, HIV/AIDS, or who receive immunosuppressive therapy after organ transplantation have higher lymphoma risk. Chronic infections like Epstein‑Barr virus, Helicobacter pylori, and hepatitis C are linked to specific subtypes. Long‑term exposure to benzene, pesticides, or solvents may also contribute. While these factors raise susceptibility, many patients develop lymphoma without any identifiable risk.
People with inherited immune‑system gene mutations, HIV/AIDS, or who receive immunosuppressive therapy after organ transplantation have higher lymphoma risk. Chronic infections like Epstein‑Barr virus, Helicobacter pylori, and hepatitis C are linked to specific subtypes. Long‑term exposure to benzene, pesticides, or solvents may also contribute. While these factors raise susceptibility, many patients develop lymphoma without any identifiable risk.
The diagnostic pathway starts with an excisional lymph‑node biopsy to obtain enough tissue for histology and immunophenotyping. Imaging studies such as PET scans assess metabolic activity, while CT scans define anatomical spread. Bone‑marrow aspiration checks for marrow involvement, and flow cytometry or molecular testing identifies specific genetic abnormalities. Staging is performed using the Ann Arbor system (Stage I‑IV) based on the extent of disease, guiding therapeutic planning.
The diagnostic pathway starts with an excisional lymph‑node biopsy to obtain enough tissue for histology and immunophenotyping. Imaging studies such as PET scans assess metabolic activity, while CT scans define anatomical spread. Bone‑marrow aspiration checks for marrow involvement, and flow cytometry or molecular testing identifies specific genetic abnormalities. Staging is performed using the Ann Arbor system (Stage I‑IV) based on the extent of disease, guiding therapeutic planning.
Chemotherapy regimens like ABVD for Hodgkin lymphoma and R‑CHOP for DLBCL remain first‑line. Radiation is added for localized disease. Immunotherapy with monoclonal antibodies (e.g., rituximab) targets CD20‑positive B‑cell lymphomas. Targeted agents such as ibrutinib inhibit specific signaling pathways in certain subtypes. Autologous or allogeneic stem‑cell transplantation offers curative potential for refractory cases. CAR‑T cell therapy, which engineers T‑cells to attack CD19, shows high response rates in relapsed NHL. Clinical trials at Liv Hospital provide access to novel checkpoint inhibitors and bispecific antibodies.
Chimeric Antigen Receptor T‑cell (CAR‑T) therapy involves extracting a patient’s T‑cells, genetically engineering them to express a receptor that binds CD19, a protein on most B‑cell lymphomas, and reinfusing them. The engineered cells proliferate and destroy cancer cells. It is typically reserved for patients with relapsed or refractory diffuse large B‑cell lymphoma, transformed follicular lymphoma, or other CD19‑positive NHLs after standard therapies have failed. Side effects can include cytokine release syndrome and neurotoxicity, which are managed in specialized centers like Liv Hospital.
After completing therapy, patients undergo regular imaging (PET/CT) and blood tests to detect early signs of relapse. Survivorship programs address psychosocial needs, nutrition, physical rehabilitation, and management of late toxicities such as secondary cancers or cardiac issues. Ongoing counseling and support groups help patients cope with anxiety and adjust to life post‑treatment. Liv Hospital’s multidisciplinary team provides coordinated long‑term surveillance to ensure optimal outcomes.
After completing therapy, patients undergo regular imaging (PET/CT) and blood tests to detect early signs of relapse. Survivorship programs address psychosocial needs, nutrition, physical rehabilitation, and management of late toxicities such as secondary cancers or cardiac issues. Ongoing counseling and support groups help patients cope with anxiety and adjust to life post‑treatment. Liv Hospital’s multidisciplinary team provides coordinated long‑term surveillance to ensure optimal outcomes.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75